BEAM - Company ID 0001745999
Beam Therapeutics Inc. trades as BEAM and has a market capitalization of $3.76 B, making it the #1657 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $139.74M, up 120.0% from the prior year and net income of -$79.99M. This page tracks Beam Therapeutics Inc. through 488 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 6 fiscal years Beam Therapeutics Inc.'s revenue grew from $18.00K to $139.74M, a compound annual growth rate of 345.0%. Net profit margin expanded from -435144.4% to -57.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| SCHEDULE 13G | - | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-17 |
| Proxy materials | DEFA14A | 2026-04-17 |
| Proxy statement | DEF 14A | 2026-04-17 |
| Insider sale notice | 144 | 2026-04-14 |
| Insider trade | 4 | 2026-04-06 |
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference | Beam Therapeutics
Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026 | Beam Therapeutics
Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Beam Therapeutics
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine | Beam Therapeutics
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Beam Therapeutics
The largest companies sharing Beam Therapeutics Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
Beam Therapeutics Inc. (BEAM) has a market capitalization of $3.76 B as of 2026-07-09, ranking #1657 among US-listed companies.
Beam Therapeutics Inc. reported revenue of $139.74M for fiscal year 2025, an increase of 120.0% year over year.
In its latest fiscal year Beam Therapeutics Inc. reported a net loss of $79.99M.